Works matching AU Chandarlapaty, Sarat

Results: 39

Genomic landscape of breast cancer in elderly patients.

Published in:

NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00781-4

By:

Selenica, Pier;
Dopeso, Higinio;
Repetto, Matteo;
Basili, Thais;
Gazzo, Andrea M.;
Schwartz, Christopher J.;
Derakhshan, Fatemeh;
Marra, Antonio;
Ferrando, Lorenzo;
Beets-Tan, Regina G. H.;
Wen, Y. H.;
Ross, Dara S.;
Brogi, Edi;
Zhang, Hong;
Norton, Larry;
Chandarlapaty, Sarat;
Razavi, Pedram;
Mandelker, Diana;
Reis-Fiho, Jorge S.;
Weigelt, Britta

Publication type:

Article

Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5‐Year Follow‐up.

Published in:

Oncologist, 2019, v. 24, n. 8, p. e646, doi. 10.1634/theoncologist.2018-0512

By:

Wang, Rui;
Smyth, Lillian M.;
Iyengar, Neil;
Chandarlapaty, Sarat;
Modi, Shanu;
Jochelson, Maxine;
Patil, Sujata;
Norton, Larry;
Hudis, Clifford A.;
Dang, Chau T.

Publication type:

Article

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.

Published in:

2017

By:

Moynahan, Mary Ellen;
Chen, David;
He, Wei;
Sung, Patricia;
Samoila, Aliaksandra;
You, Daoqi;
Bhatt, Trusha;
Patel, Parul;
Ringeisen, Francois;
Hortobagyi, Gabriel N;
Baselga, Jose;
Chandarlapaty, Sarat

Publication type:

journal article

F-FDG PET/CT in metastatic invasive lobular breast cancer.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.247882

By:

Ulaner, Gary A.;
Jhaveri, Komal;
Chandarlapaty, Sarat;
Hatzoglou, Vaios;
Riedl, Christopher C.;
Lewis, Jason S.;
Mauguen, Audrey

Publication type:

Article

Head-to-head evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.247882

By:

Ulaner, Gary A.;
Jhaveri, Komal;
Chandarlapaty, Sarat;
Hatzoglou, Vaios;
Riedl, Christopher C.;
Lewis, Jason S.;
Mauguen, Audrey

Publication type:

Article

Head-to-head evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.247882

By:

Ulaner, Gary A.;
Jhaveri, Komal;
Chandarlapaty, Sarat;
Hatzoglou, Vaios;
Riedl, Christopher C.;
Lewis, Jason S.;
Mauguen, Audrey

Publication type:

Article

Head-to-head evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.247882

By:

Ulaner, Gary A.;
Jhaveri, Komal;
Chandarlapaty, Sarat;
Hatzoglou, Vaios;
Riedl, Christopher C.;
Lewis, Jason S.;
Mauguen, Audrey

Publication type:

Article

Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.

Published in:

Journal of Nuclear Medicine, 2016, v. 57, n. 10, p. 1523, doi. 10.2967/jnumed.115.172031

By:

Ulaner, Gary A.;
Hyman, David M.;
Ross, Dara S.;
Corben, Adriana;
Chandarlapaty, Sarat;
Goldfarb, Shari;
McArthur, Heather;
Erinjeri, Joseph P.;
Solomon, Stephen B.;
Kolb, Hartmuth;
Lyashchenko, Serge K.;
Lewis, Jason S.;
Carrasquillo, Jorge A.

Publication type:

Article

ESR1 Mutations Portend Worse Survival in ER+ Advanced Breast Cancer.

Published in:

Personalized Medicine in Oncology, 2016, v. 5, n. 1, p. 42

By:

Chandarlapaty, Sarat

Publication type:

Article

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.

Published in:

Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-27093-y

By:

Smith, Alison E.;
Ferraro, Emanuela;
Safonov, Anton;
Morales, Cristina Bernado;
Lahuerta, Enrique J. Arenas;
Li, Qing;
Kulick, Amanda;
Ross, Dara;
Solit, David B.;
de Stanchina, Elisa;
Reis-Filho, Jorge;
Rosen, Neal;
Arribas, Joaquín;
Razavi, Pedram;
Chandarlapaty, Sarat

Publication type:

Article

Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.

Published in:

2021

By:

Bo Liu;
Zhaoqi Liu;
Sisi Chen;
Ki, Michelle;
Erickson, Caroline;
Reis-Filho, Jorge S.;
Durham, Benjamin H.;
Qing Chang;
de Stanchina, Elisa;
Yiwei Sun;
Rabadan, Raul;
Abdel-Wahab, Omar;
Chandarlapaty, Sarat;
Liu, Bo;
Liu, Zhaoqi;
Chen, Sisi;
Chang, Qing;
Sun, Yiwei

Publication type:

journal article

Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.

Published in:

JNCI Cancer Spectrum, 2019, v. 3, n. 4, p. N.PAG, doi. 10.1093/jncics/pkz050

By:

Dowling, Ryan J O;
Kalinsky, Kevin;
Hayes, Daniel F;
Bidard, Francois-Clement;
Cescon, David W;
Chandarlapaty, Sarat;
Deasy, Joseph O;
Dowsett, Mitch;
Gray, Robert J;
Henry, N Lynn;
Meric-Bernstam, Funda;
Perlmutter, Jane;
Sledge, George W;
Bratman, Scott V;
Carey, Lisa A;
Chang, Martin C;
DeMichele, Angela;
Ennis, Marguerite;
Jerzak, Katarzyna J;
Korde, Larissa A

Publication type:

Article

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.

Published in:

JNCI Cancer Spectrum, 2019, v. 3, n. 4, p. N.PAG, doi. 10.1093/jncics/pkz049

By:

Dowling, Ryan J O;
Sparano, Joseph A;
Goodwin, Pamela J;
Bidard, Francois-Clement;
Cescon, David W;
Chandarlapaty, Sarat;
Deasy, Joseph O;
Dowsett, Mitch;
Gray, Robert J;
Henry, N Lynn;
Meric-Bernstam, Funda;
Perlmutter, Jane;
Sledge, George W;
Thorat, Mangesh A;
Bratman, Scott V;
Carey, Lisa A;
Chang, Martin C;
DeMichele, Angela;
Ennis, Marguerite;
Jerzak, Katarzyna J

Publication type:

Article

Whole‐exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma.

Published in:

Journal of Pathology: Clinical Research, 2021, v. 7, n. 2, p. 113, doi. 10.1002/cjp2.190

By:

D'Alfonso, Timothy M;
Pareja, Fresia;
Da Cruz Paula, Arnaud;
Vahdatinia, Mahsa;
Gazzo, Andrea;
Ferrando, Lorenzo;
da Silva, Edaise M;
Cheng, Esther;
Sclafani, Lisa;
Chandarlapaty, Sarat;
Zhang, Hong;
Hoda, Syed A;
Wen, Hannah Y;
Brogi, Edi;
Weigelt, Britta;
Reis‐Filho, Jorge S

Publication type:

Article

Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers.

Published in:

Science Translational Medicine, 2025, v. 17, n. 801, p. 1, doi. 10.1126/scitranslmed.adk7786

By:

Cai, Yanyan;
Zhao, Peihua;
Wu, Fan;
Zhao, Huiyong;
Shao, Hong;
Marra, Antonio;
Patel, Payal;
O'Connell, Elizabeth;
Fink, Emma;
Miele, Matthew M.;
Li, Zhuoning;
De Stanchina, Elisa;
Cocco, Emiliano;
Razavi, Pedram;
Toska, Eneda;
Fanning, Sean W.;
Xu, Guotai;
Sablina, Anna A.;
Scaltriti, Maurizio;
Chandarlapaty, Sarat

Publication type:

Article

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.

Published in:

Nature Genetics, 2015, v. 47, n. 10, p. 1212, doi. 10.1038/ng.3391

By:

Janiszewska, Michalina;
Liu, Lin;
Almendro, Vanessa;
Kuang, Yanan;
Paweletz, Cloud;
Reis-Filho, Jorge S;
Arteaga, Carlos L;
Michor, Franziska;
Polyak, Kornelia;
Sakr, Rita A;
King, Tari A;
Weigelt, Britta;
Hanker, Ariella B;
Chandarlapaty, Sarat;
Park, So Yeon

Publication type:

Article

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Published in:

Nature Genetics, 2013, v. 45, n. 12, p. 1439, doi. 10.1038/ng.2822

By:

Toy, Weiyi;
Shen, Yang;
Won, Helen;
Green, Bradley;
Sakr, Rita A;
Will, Marie;
Li, Zhiqiang;
Gala, Kinisha;
Fanning, Sean;
King, Tari A;
Hudis, Clifford;
Chen, David;
Taran, Tetiana;
Hortobagyi, Gabriel;
Greene, Geoffrey;
Berger, Michael;
Baselga, José;
Chandarlapaty, Sarat

Publication type:

Article

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.

Published in:

NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00592-5

By:

Moss, Nelson S.;
Singh, Jolene M.;
Reiner, Anne S.;
Drago, Joshua Z.;
Modi, Shanu;
Seidman, Andrew D.;
Chandarlapaty, Sarat;
Ross, Dara S.

Publication type:

Article

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.

Published in:

NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00380-7

By:

Ferraro, Emanuela;
Singh, Jasmeet;
Patil, Sujata;
Razavi, Pedram;
Modi, Shanu;
Chandarlapaty, Sarat;
Barrio, Andrea V.;
Malani, Rachna;
Mellinghoff, Ingo K.;
Boire, Adrienne;
Wen, Hannah Y.;
Brogi, Edi;
Seidman, Andrew D.;
Norton, Larry;
Robson, Mark E.;
Dang, Chau T.

Publication type:

Article

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

Published in:

2016

By:

Jhaveri, Komal;
Chandarlapaty, Sarat;
Iyengar, Neil;
Morris, Patrick G.;
Corben, Adriana D.;
Patil, Sujata;
Akram, Muzaffar;
Towers, Russell;
Sakr, Rita A.;
King, Tari A.;
Norton, Larry;
Rosen, Neal;
Hudis, Clifford;
Modi, Shanu

Publication type:

journal article

A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer.

Published in:

Clinical Breast Cancer, 2014, v. 14, n. 3, p. 154, doi. 10.1016/j.clbc.2013.12.012

By:

Jhaveri, Komal;
Chandarlapaty, Sarat;
Lake, Diana;
Gilewski, Teresa;
Robson, Mark;
Goldfarb, Shari;
Drullinsky, Pamela;
Sugarman, Steven;
Leiblich, Carolyn Wasserheit;
Fasano, Julie;
Moynahan, Mary Ellen;
D'Andrea, Gabriella;
Lim, Kristina;
Reddington, Laura;
Haque, Sofia;
Patil, Sujata;
Bauman, Lynne;
Vukovic, Vojo;
El-Hariry, Iman;
Hudis, Clifford

Publication type:

Article

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.

Published in:

OncoImmunology, 2017, v. 6, n. 3, p. N.PAG, doi. 10.1080/2162402X.2016.1267891

By:

Lopez-Albaitero, Andres;
Xu, Hong;
Guo, Hongfen;
Wang, Linlin;
Wu, Zhihao;
Tran, Hoa;
Chandarlapaty, Sarat;
Scaltriti, Maurizio;
Janjigian, Yelena;
de Stanchina, Elisa;
Cheung, Nai-Kong V.

Publication type:

Article

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.

Published in:

Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-31668-8

By:

Bardia, Aditya;
Chandarlapaty, Sarat;
Linden, Hannah M.;
Ulaner, Gary A.;
Gosselin, Alice;
Cartot-Cotton, Sylvaine;
Cohen, Patrick;
Doroumian, Séverine;
Paux, Gautier;
Celanovic, Marina;
Pelekanou, Vasiliki;
Ming, Jeffrey E.;
Ternès, Nils;
Bouaboula, Monsif;
Lee, Joon Sang;
Bauchet, Anne-Laure;
Campone, Mario

Publication type:

Article

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Published in:

Science Translational Medicine, 2015, v. 7, n. 313, p. 1, doi. 10.1126/scitranslmed.aac7551

By:

Schiavon, Gaia;
Hrebien, Sarah;
Garcia-Murillas, Isaac;
Cutts, Rosalind J.;
Pearson, Alex;
Tarazona, Noelia;
Fenwick, Kerry;
Iwanka Kozarewa;
Lopez-Knowles, Elena;
Ribas, Ricardo;
Nerurkar, Ashutosh;
Osin, Peter;
Chandarlapaty, Sarat;
Martin, Lesley-Ann;
Dowsett, Mitch;
Smith, Ian E.;
Turner, Nicholas C.

Publication type:

Article

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.

Published in:

Genome Medicine, 2020, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13073-020-00774-x

By:

Mateo, Lidia;
Duran-Frigola, Miquel;
Gris-Oliver, Albert;
Palafox, Marta;
Scaltriti, Maurizio;
Razavi, Pedram;
Chandarlapaty, Sarat;
Arribas, Joaquin;
Bellet, Meritxell;
Serra, Violeta;
Aloy, Patrick

Publication type:

Article

Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.

Published in:

2018

By:

Scott, Jessica M.;
Iyengar, Neil M.;
Nilsen, Tormod S.;
Michalski, Meghan;
Thomas, Samantha M.;
Herndon, II, James;
Sasso, John;
Yu, Anthony;
Chandarlapaty, Sarat;
Dang, Chau T.;
Comen, Elizabeth A.;
Dickler, Maura N.;
Peppercorn, Jeffrey M.;
Jones, Lee W.;
Herndon, James 2nd

Publication type:

journal article

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.

Published in:

Breast Cancer Research, 2013, v. 15, n. 6, p. 3, doi. 10.1186/bcr3577

By:

Hudis, Clifford;
Swanton, Charles;
Janjigian, Yelena Y.;
Lee, Ray;
Sutherland, Stephanie;
Lehman, Robert;
Chandarlapaty, Sarat;
Hamilton, Nicola;
Gajria, Devika;
Knowles, James;
Shah, Jigna;
Shannon, Keith;
Tetteh, Ernestina;
Sullivan, Daniel M.;
Moreno, Carolina;
Yan, Li;
Han, Hyo Sook

Publication type:

Article

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.

Published in:

2013

By:

Hudis, Clifford;
Swanton, Charles;
Janjigian, Yelena Y;
Lee, Ray;
Sutherland, Stephanie;
Lehman, Robert;
Chandarlapaty, Sarat;
Hamilton, Nicola;
Gajria, Devika;
Knowles, James;
Shah, Jigna;
Shannon, Keith;
Tetteh, Ernestina;
Sullivan, Daniel M;
Moreno, Carolina;
Yan, Li;
Han, Hyo;
Han, Hyo Sook

Publication type:

journal article

PTEN is a protein tyrosine phosphatase for IRS1.

Published in:

Nature Structural & Molecular Biology, 2014, v. 21, n. 6, p. 522, doi. 10.1038/nsmb.2828

By:

Shi, Yuji;
Wang, Junru;
Chandarlapaty, Sarat;
Cross, Justin;
Thompson, Craig;
Rosen, Neal;
Jiang, Xuejun

Publication type:

Article

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.

Published in:

NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00699-3

By:

Mai, Nicholas;
dos Anjos, Carlos H.;
Razavi, Pedram;
Safonov, Anton;
Patil, Sujata;
Chen, Yuan;
Drago, Joshua Z.;
Modi, Shanu;
Bromberg, Jacqueline F.;
Dang, Chau T.;
Liu, Dazhi;
Norton, Larry;
Robson, Mark;
Chandarlapaty, Sarat;
Jhaveri, Komal

Publication type:

Article

Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.

Published in:

Histopathology, 2020, v. 76, n. 6, p. 865, doi. 10.1111/his.14057

By:

Pareja, Fresia;
Toss, Michael S;
Geyer, Felipe C;
Silva, Edaise M;
Vahdatinia, Mahsa;
Sebastiao, Ana Paula M;
Selenica, Pier;
Szatrowski, Austin;
Edelweiss, Marcia;
Wen, Hannah Y;
Mihai, Raluca;
Varga, Zsuzsanna;
Foschini, Maria P;
Rubin, Brian P;
Ellis, Ian O;
Chandarlapaty, Sarat;
Jungbluth, Achim A;
Brogi, Edi;
Weigelt, Britta;
Reis‐Filho, Jorge S

Publication type:

Article

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling.

Published in:

PLoS ONE, 2008, v. 3, n. 8, p. 1, doi. 10.1371/journal.pone.0003065

By:

Qing-Bai She;
Chandarlapaty, Sarat;
Qing Ye;
Lobo, Jose;
Haskell, Kathleen M.;
Leander, Karen R.;
DeFeo-Jones, Deborah;
Huber, Hans E.;
Rosen, Neal

Publication type:

Article

TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.

Published in:

NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00250-8

By:

da Silva, Edaise M.;
Selenica, Pier;
Vahdatinia, Mahsa;
Pareja, Fresia;
Da Cruz Paula, Arnaud;
Ferrando, Lorenzo;
Gazzo, Andrea M.;
Dopeso, Higinio;
Ross, Dara S.;
Bakhteri, Ariya;
Riaz, Nadeem;
Chandarlapaty, Sarat;
Razavi, Pedram;
Norton, Larry;
Wen, Hannah Y.;
Brogi, Edi;
Weigelt, Britta;
Zhang, Hong;
Reis-Filho, Jorge S.

Publication type:

Article

The genomic landscape of metastatic histologic special types of invasive breast cancer.

Published in:

NPJ Breast Cancer, 2020, v. 6, n. 1, p. N.PAG, doi. 10.1038/s41523-020-00195-4

By:

Pareja, Fresia;
Ferrando, Lorenzo;
Lee, Simon S. K.;
Beca, Francisco;
Selenica, Pier;
Brown, David N.;
Farmanbar, Amir;
Da Cruz Paula, Arnaud;
Vahdatinia, Mahsa;
Zhang, Hong;
Zoppoli, Gabriele;
Wen, Hannah Y.;
Brogi, Edi;
Robson, Mark E.;
Razavi, Pedram;
Chandarlapaty, Sarat;
Weigelt, Britta;
Reis-Filho, Jorge S.

Publication type:

Article

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.

Published in:

eLife, 2016, p. 1, doi. 10.7554/eLife.12792

By:

Fanning, Sean W.;
Mayne, Christopher G.;
Dharmarajan, Venkatasubramanian;
Carlson, Kathryn E.;
Martin, Teresa A.;
Novick, Scott J.;
Weiyi Toy;
Green, Bradley;
Panchamukhi, Srinivas;
Katzenellenbogen, Benita S.;
Tajkhorshid, Emad;
Griffin, Patrick R.;
Yang Shen;
Chandarlapaty, Sarat;
Katzenellenbogen, John A.;
Greene, Geoffrey L.

Publication type:

Article

Reversible histone glycation is associated with disease-related changes in chromatin architecture.

Published in:

Nature Communications, 2019, v. 10, n. 1, p. 1, doi. 10.1038/s41467-019-09192-z

By:

Qingfei Zheng;
Omans, Nathaniel D.;
Leicher, Rachel;
Osunsade, Adewola;
Agustinus, Albert S.;
Finkin-Groner, Efrat;
D’Ambrosio, Hannah;
Bo Liu;
Chandarlapaty, Sarat;
Shixin Liu;
David, Yael

Publication type:

Article

Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.

Published in:

2019

By:

Tonsing-Carter, Eva;
Hernandez, Kyle M.;
Kim, Caroline R.;
Harkless, Ryan V.;
Oh, Alyce;
Bowie, Kathleen R.;
West-Szymanski, Diana C.;
Betancourt-Ponce, Mayra A.;
Green, Bradley D.;
Lastra, Ricardo R.;
Fleming, Gini F.;
Chandarlapaty, Sarat;
Conzen, Suzanne D.

Publication type:

journal article

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.

Published in:

2017

By:

Jhaveri, Komal;
Rui Wang;
Teplinsky, Eleonora;
Chandarlapaty, Sarat;
Solit, David;
Cadoo, Karen;
Speyer, James;
D'Andrea, Gabriella;
Adams, Sylvia;
Patil, Sujata;
Haque, Sofia;
O'Neill, Tara;
Friedman, Kent;
Esteva, Francisco J.;
Hudis, Clifford;
Modi, Shanu;
Wang, Rui

Publication type:

journal article

Independent real‐world application of a clinical‐grade automated prostate cancer detection system.

Published in:

Journal of Pathology, 2021, v. 254, n. 2, p. 147, doi. 10.1002/path.5662

By:

Silva, Leonard M;
Pereira, Emilio M;
Salles, Paulo GO;
Godrich, Ran;
Ceballos, Rodrigo;
Kunz, Jeremy D;
Casson, Adam;
Viret, Julian;
Chandarlapaty, Sarat;
Ferreira, Carlos Gil;
Ferrari, Bruno;
Rothrock, Brandon;
Raciti, Patricia;
Reuter, Victor;
Dogdas, Belma;
DeMuth, George;
Sue, Jillian;
Kanan, Christopher;
Grady, Leo;
Fuchs, Thomas J

Publication type:

Article

Works matching AU Chandarlapaty, Sarat

Genomic landscape of breast cancer in elderly patients.

Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5‐Year Follow‐up.

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR<sup>+</sup>, HER2<sup>-</sup> advanced breast cancer: results from BOLERO-2.

F-FDG PET/CT in metastatic invasive lobular breast cancer.

Head-to-head evaluation of <sup>18</sup>F-FES and <sup>18</sup>F-FDG PET/CT in metastatic invasive lobular breast cancer.

Head-to-head evaluation of <sup>18</sup>F-FES and <sup>18</sup>F-FDG PET/CT in metastatic invasive lobular breast cancer.

Head-to-head evaluation of <sup>18</sup>F-FES and <sup>18</sup>F-FDG PET/CT in metastatic invasive lobular breast cancer.

Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using <sup>89</sup>Zr-Trastuzumab PET/CT.

ESR1 Mutations Portend Worse Survival in ER+ Advanced Breast Cancer.

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.

Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.

Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.

Whole‐exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma.

Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers.

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer.

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.

Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.

PTEN is a protein tyrosine phosphatase for IRS1.

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.

Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling.

TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.

The genomic landscape of metastatic histologic special types of invasive breast cancer.

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.

Reversible histone glycation is associated with disease-related changes in chromatin architecture.

Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.

Independent real‐world application of a clinical‐grade automated prostate cancer detection system.